(Total Views: 378)
Posted On: 11/08/2017 1:01:06 PM
Post# of 1460
From a science respected poster IMHO, on IHUB,
Fletch
falconer66a Wednesday, 11/08/17 11:34:07 AM
Re: mrplmer post# 129548
Post # of 129596
Unique Anavex 2-73 Traits
1. Unique, Effective Mechanism of Action. Anavex 2-73 addresses central nervous system diseases differently from any other drug currently or prospectively in use. It is a sigma-1 receptor agonist. There are a number of these, but none that work as effectively and safely as Anavex 2-73. The molecule causes dissembled rough endoplasmic reticula and mitochondria to re-connect and function collaboratively. It is well recognized that most CNS diseases involve mitochondrial dysfunction. Anavex 2-73 is able to re-establish the proper, healthful endoplasmic reticular/mitochondrial connection. With this, calcium ion exchange and adenosine triphosphate interchange (mitochondrion to the ER) can occur, restoring full, natural cellular functions, which result in clearance of the waste proteins (beta-amyloids, tau tangles) that cause Alzheimer's disease symptoms.
2. Ease of Administration. Anavex 2-73 is efficiently absorbed in the gastrointestinal tract, and once in the blood stream readily crosses the blood/brain barrier. This will allow for simple oral administration, no intravenous drip procedures. The blood/brain barrier restricts many drugs and molecules from nervous tissues. Propitiously, this is not a problem with Anavex 2-73.
3. Treats Upstream Portions of Alzheimer’s Disease. For Alzheimer’s, Anavex 2-73 targets upstream disease processes, obviating a multitude of downstream symptoms. Existing treatment approaches (all of which have failed) target the removal of the waste proteins, the beta-amyloids and tau tangles. Anavex 2-73 restores proper cell function, where enzymes can be once again synthesized (in the endoplasmic reticulum, using ample ATP from the adjacent, now re-connected mitochondria, etc.). Anavex 2-73 treats the upstream causes of Alzheimer’s symptoms, the dissembled ER and mitochondria, with no downstream complications (waste protein accumulations).
4. No Negating Safety or Tolerability Issues. Anavex 2-73 has demonstrated remarkable safety outcomes. In an early trial of Anavex 2-73 in Australia, the safety and tolerability profiles of the drug were very favorable. The only Adverse Events were at Levels 1 and 2, such as dizziness or headache. None of the adverse events were at a degree that would prevent or restrict the use of the drug to treat or prevent Alzheimer’s disease. This is uncommon. Most drugs treating neurological conditions have a number of side effects of negating consequence. Not so with Anavex 2-73.
5. Stops or Reverses Alzheimer’s Disease Progression. Anavex 2-73 a) stops or reverses the progression of Alzheimer’s cognitive decline, and b) maintains or improves cognition for at least 107 months. It does not lose efficacy during this time. Existing Standard of Care Alzheimer’s drugs do slow or, for a time prevent cognition decline; but only for short intervals (a few months to a year or so); whereupon the lethal course of the disease resumes. Additionally, clinical evidence shows that earlier administration of Anavex 2-73, before Alzheimer’s symptoms become fully burdensome, can keep the disease from degeneratively progressing. It has prophylactic capabilities.
Fletch
falconer66a Wednesday, 11/08/17 11:34:07 AM
Re: mrplmer post# 129548
Post # of 129596
Unique Anavex 2-73 Traits
1. Unique, Effective Mechanism of Action. Anavex 2-73 addresses central nervous system diseases differently from any other drug currently or prospectively in use. It is a sigma-1 receptor agonist. There are a number of these, but none that work as effectively and safely as Anavex 2-73. The molecule causes dissembled rough endoplasmic reticula and mitochondria to re-connect and function collaboratively. It is well recognized that most CNS diseases involve mitochondrial dysfunction. Anavex 2-73 is able to re-establish the proper, healthful endoplasmic reticular/mitochondrial connection. With this, calcium ion exchange and adenosine triphosphate interchange (mitochondrion to the ER) can occur, restoring full, natural cellular functions, which result in clearance of the waste proteins (beta-amyloids, tau tangles) that cause Alzheimer's disease symptoms.
2. Ease of Administration. Anavex 2-73 is efficiently absorbed in the gastrointestinal tract, and once in the blood stream readily crosses the blood/brain barrier. This will allow for simple oral administration, no intravenous drip procedures. The blood/brain barrier restricts many drugs and molecules from nervous tissues. Propitiously, this is not a problem with Anavex 2-73.
3. Treats Upstream Portions of Alzheimer’s Disease. For Alzheimer’s, Anavex 2-73 targets upstream disease processes, obviating a multitude of downstream symptoms. Existing treatment approaches (all of which have failed) target the removal of the waste proteins, the beta-amyloids and tau tangles. Anavex 2-73 restores proper cell function, where enzymes can be once again synthesized (in the endoplasmic reticulum, using ample ATP from the adjacent, now re-connected mitochondria, etc.). Anavex 2-73 treats the upstream causes of Alzheimer’s symptoms, the dissembled ER and mitochondria, with no downstream complications (waste protein accumulations).
4. No Negating Safety or Tolerability Issues. Anavex 2-73 has demonstrated remarkable safety outcomes. In an early trial of Anavex 2-73 in Australia, the safety and tolerability profiles of the drug were very favorable. The only Adverse Events were at Levels 1 and 2, such as dizziness or headache. None of the adverse events were at a degree that would prevent or restrict the use of the drug to treat or prevent Alzheimer’s disease. This is uncommon. Most drugs treating neurological conditions have a number of side effects of negating consequence. Not so with Anavex 2-73.
5. Stops or Reverses Alzheimer’s Disease Progression. Anavex 2-73 a) stops or reverses the progression of Alzheimer’s cognitive decline, and b) maintains or improves cognition for at least 107 months. It does not lose efficacy during this time. Existing Standard of Care Alzheimer’s drugs do slow or, for a time prevent cognition decline; but only for short intervals (a few months to a year or so); whereupon the lethal course of the disease resumes. Additionally, clinical evidence shows that earlier administration of Anavex 2-73, before Alzheimer’s symptoms become fully burdensome, can keep the disease from degeneratively progressing. It has prophylactic capabilities.
(0)
(0)Scroll down for more posts ▼
